These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9023649)

  • 41. The effect of food on the bioavailability of temafloxacin. A review of 3 studies.
    Granneman GR; Mukherjee D
    Clin Pharmacokinet; 1992; 22 Suppl 1():48-56. PubMed ID: 1319871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses.
    Giguère S; Sweeney RW; Bélanger M
    Am J Vet Res; 1996 Jul; 57(7):1025-30. PubMed ID: 8807015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of temafloxacin after multiple oral administration.
    Granneman GR
    Clin Pharmacokinet; 1992; 22 Suppl 1():14-23. PubMed ID: 1319867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of rufloxacin in healthy volunteers.
    Segre G; Cerretani D; Moltoni L; Urso R
    Eur J Clin Pharmacol; 1992; 42(1):101-5. PubMed ID: 1311685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.
    Allen A; Bygate E; Oliver S; Johnson M; Ward C; Cheon AJ; Choo YS; Kim IC
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1604-8. PubMed ID: 10817716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic evaluation of enrofloxacin in chickens.
    Abd el-Aziz MI; Aziz MA; Soliman FA; Afify NA
    Br Poult Sci; 1997 May; 38(2):164-8. PubMed ID: 9158891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing.
    Mant TG
    Am J Med; 1992 Apr; 92(4A):26S-32S. PubMed ID: 1316066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data.
    Frame B; Koup J; Miller R; Lalonde R
    Clin Pharmacokinet; 2001; 40(4):307-15. PubMed ID: 11368295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.
    Ritz M; Lode H; Fassbender M; Borner K; Koeppe P; Nord CE
    Antimicrob Agents Chemother; 1994 Mar; 38(3):455-9. PubMed ID: 8203837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of ranitidine on renal clearance of lomefloxacin.
    Sudoh T; Fujimura A; Harada K; Sunaga K; Ohmori M; Sakamoto K
    Eur J Clin Pharmacol; 1996; 51(1):95-8. PubMed ID: 8880059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of rufloxacin in patients with impaired renal function.
    Perry G; Mant TG; Morrison PJ; Sacks S; Woodcook J; Wise R; Imbimbo BP
    Antimicrob Agents Chemother; 1993 Apr; 37(4):637-41. PubMed ID: 8388194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone.
    Oh H; Nord CE; Barkholt L; Hedberg M; Edlund C
    Infection; 2000 Sep; 28(5):272-7. PubMed ID: 11073132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and biliary elimination of temafloxacin in pigs.
    Jehl F; Bresler L; Koechlin C; Merle-Melet M; Didelot JP; Hazebroucq J
    J Antimicrob Chemother; 1992 Aug; 30(2):189-96. PubMed ID: 1328135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.
    Efthymiopoulos C; Bramer SL; Maroli A; Flaherty JF; Wolfe E; Bass N; Somberg K
    Clin Pharmacokinet; 1997; 33 Suppl 1():25-31. PubMed ID: 9433653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
    Kovarik JM; Hoepelman AI; Smit JM; Sips PA; Rozenberg-Arska M; Glerum JH; Verhoef J
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2458-61. PubMed ID: 1336948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of enrofloxacin after intravenous and intramuscular injection in rabbits.
    Cabanes A; Arboix M; Garcia Anton JM; Reig F
    Am J Vet Res; 1992 Nov; 53(11):2090-3. PubMed ID: 1334640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats.
    Park YH; Jung BH; Chung BC; Park J; Mitoma C
    Drug Metab Dispos; 1997 Sep; 25(9):1101-3. PubMed ID: 9311628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Marbofloxacin in equine medicine: have we got the doses right?
    Lees P; Aliabadi FS
    Equine Vet J; 2002 Jul; 34(4):322-5. PubMed ID: 12117100
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.